539 related articles for article (PubMed ID: 18852532)
1. 1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.
St-Arnaud R; Arabian A; Yu VW; Akhouayri O; Knutson JC; Strugnell SA
J Endocrinol Invest; 2008 Aug; 31(8):711-7. PubMed ID: 18852532
[TBL] [Abstract][Full Text] [Related]
2. Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D3: biochemical, histomorphometric, and biomechanical analyses.
Dardenne O; Prudhomme J; Hacking SA; Glorieux FH; St-Arnaud R
J Bone Miner Res; 2003 Apr; 18(4):637-43. PubMed ID: 12674324
[TBL] [Abstract][Full Text] [Related]
3. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
Finch JL; Brown AJ; Slatopolsky E
J Am Soc Nephrol; 1999 May; 10(5):980-5. PubMed ID: 10232683
[TBL] [Abstract][Full Text] [Related]
7. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1).
Dardenne O; Prud'homme J; Hacking SA; Glorieux FH; St-Arnaud R
Bone; 2003 Apr; 32(4):332-40. PubMed ID: 12689675
[TBL] [Abstract][Full Text] [Related]
8. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
Brown AJ; Ritter CS; Knutson JC; Strugnell SA
Nephrol Dial Transplant; 2006 Mar; 21(3):644-50. PubMed ID: 16221703
[TBL] [Abstract][Full Text] [Related]
9. 1alpha-hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats.
Erben RG; Bante U; Birner H; Stangassinger M
Calcif Tissue Int; 1997 May; 60(5):449-56. PubMed ID: 9115163
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats.
Shinki T; Ueno Y; DeLuca HF; Suda T
Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8253-8. PubMed ID: 10393981
[TBL] [Abstract][Full Text] [Related]
11. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia.
Slatopolsky E; Finch J; Ritter C; Denda M; Morrissey J; Brown A; DeLuca H
Am J Kidney Dis; 1995 Nov; 26(5):852-60. PubMed ID: 7485144
[TBL] [Abstract][Full Text] [Related]
12. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia.
St-Arnaud R; Arabian A; Akhouayri O; Knutson JC; Strugnell SA
Nephron Exp Nephrol; 2011; 119(3):e67-74. PubMed ID: 21849802
[TBL] [Abstract][Full Text] [Related]
14. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
Martin KJ; González EA; Gellens ME; Hamm LL; Abboud H; Lindberg J
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
[TBL] [Abstract][Full Text] [Related]
15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
16. Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis.
Nguyen-Yamamoto L; Bolivar I; Strugnell SA; Goltzman D
J Am Soc Nephrol; 2010 Oct; 21(10):1713-23. PubMed ID: 20651168
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
18. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets.
Dardenne O; Prud'homme J; Arabian A; Glorieux FH; St-Arnaud R
Endocrinology; 2001 Jul; 142(7):3135-41. PubMed ID: 11416036
[TBL] [Abstract][Full Text] [Related]
19. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals.
Murayama A; Takeyama K; Kitanaka S; Kodera Y; Kawaguchi Y; Hosoya T; Kato S
Endocrinology; 1999 May; 140(5):2224-31. PubMed ID: 10218975
[TBL] [Abstract][Full Text] [Related]
20. Generation of 1,25-dihydroxyvitamin D
Nishikawa M; Yasuda K; Takamatsu M; Abe K; Nakagawa K; Tsugawa N; Hirota Y; Tanaka K; Yamashita S; Ikushiro S; Suda T; Okano T; Sakaki T
J Steroid Biochem Mol Biol; 2019 Jan; 185():71-79. PubMed ID: 30031146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
